Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-05
1998-09-15
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3800, A61K 3816
Patent
active
058078240
ABSTRACT:
Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.
REFERENCES:
patent: 4620948 (1986-11-01), Builder
patent: 4686100 (1987-08-01), Raffin et al.
patent: 4692511 (1987-09-01), Hahn
patent: 4772584 (1988-09-01), Cleary
patent: 4937189 (1990-06-01), Davidow et al.
patent: 5177190 (1993-01-01), Rollins et al.
patent: 5190922 (1993-03-01), Luly et al.
Kinoshita, Immunology Today 12:291-300 (1991).
Muller-Eberhard, Ann. Rev. Biochem 57:321-347 (1988).
Nilsson et al., J. Immunol. 114:815-822 (1975).
Hugli, CRC Crit. Rev. Immunol. 1:321-366 (1981).
Bautsch et al., Immunobiol. 185:41-52 (1992).
Fernanadez, et al., J. Immunol. 120:109-115 (1978).
Bautsch et al., Biochem J. 288:261-266 (1992).
Haslett et al., J. Immunol. 142:3510-3517 (1989).
Mollison et al., Proc. Nat'l. Acad. Sci. USA 86:292-296 (1989).
Hammerschmidt, et al., Lancet 1:947-49 (1980).
Kawai et al., J. Med. Chem. 35:220-223 (1992).
Kawai et al., J. Med. Chem. 34:2068-2071 (1992).
Or et al., J. Med. Chem. 35:402-406 (1992).
Mollison et al., "C5a Structural Requirements for Neutryphil Receptor Interaction," in Progress in Inflammation Research and Therapy, Birkhaus Verlag, Basel (1991), pp. 17-21.
Oppermann et al., J. Immunol. 151(7):3785-3794 (1993).
Chenoweth et al., Mol. Immunol. 17:151-161 (1980).
Seligmann et al., Agents and Actions 21:375-378 (1987).
Fernanadez et al., J. Biol. Chem. 253:6955-6964 (1978).
Mandecki et al., Proc. Nat'l. Acad. Sci. USA 82:3543-3547 (1985).
Carney et al., Protein Science 2:1391-1399 (1993).
Goff et al., Proc. Nat'l. Acad. Sci. USA 81:6647-6651 (1984).
Harris et al., J. Receptor Res. 11:115-128 (1991).
Rollins et al., J. Biol. Chem. 263:520-526 (1988).
Braunwalder et al., Mol. Immunol. 29(11):1319-1324 (1992).
Hensens et al., J. Antibiotics 44(2):249-254 (1991).
Greer et al. "Comparative Modeling of Proteins in the Complement Pathway" in Computer-Assisted Modeling of Receptor-Ligand Interactions: Theoretical Aspects and Applications to Drug Design: pp. 385-397 (1989).
Ayesh et al., J. Immunol. 144(8):3066-70 (1990).
Gerard et al., J. Reticuloend. Soc. 26:711-18 (1979).
Ember et al., J. Immunol. 148(10):3165-73 (1992).
Chenoweth et al., Proc. Natl. Acad. Sci. USA 75:3943-3947 (1978).
Gerard et al., Annv. Rev. Immunol. 12:775-808 (1994).
Ngo et al. (1994) Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. In: The Protein Folding Problem and Tertiary Structure Prediction. Eds. Merz et al., Birkhauser, Boston, MA, pp. 491-495, Jan. 1994.
Rudinger (1976) Characterstics of the amino acids as components of a peptide hormone sequence. In: Peptide Hormones. Ed. J. A. Parsons, University Park Press, Baltimore, MD, pp. 1-7, Jun. 1976.
Boyar William C.
Galakatos Nicholas G.
Heeke Gino Van
Schmitz Albert
van Oostrum Jan
Ciba-Geigy Corporation
Stole Einar
Wax Robert A.
LandOfFree
C5A receptor antagonists having substantially no agonist activit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C5A receptor antagonists having substantially no agonist activit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C5A receptor antagonists having substantially no agonist activit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-86952